About InMed Pharmaceuticals Inc. - Common Shares (INM)
Inmed Pharmaceuticals Inc. is a biopharmaceutical company focused on the development of innovative therapies derived from cannabinoids. The company specializes in advancing its proprietary drug development programs, particularly for conditions related to the central nervous system, as well as other unmet medical needs. By leveraging its expertise in cannabinoid-based technology and precision medicine, Inmed aims to address critical health challenges and improve patient outcomes through its unique formulations and delivery methods. Read More
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused...
Wondering how the US markets performed one hour before the close of the markets on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
InMed Pharmaceuticals (NASDAQ: INM), a pharmaceutical company developing small molecule drug candidates for diseases with high unmet medical needs, announced new preclinical data showing that INM-901 significantly reduces inflammation in ex vivo models of neuroinflammation. The compound demonstrated a dose-dependent and statistically significant reduction in pro-inflammatory cytokines IL-6, IL-1β, IL-2, KC/Gro, and inflammasome marker NLRP3—key factors in Alzheimer’s disease progression. Notably, the effects were independent of amyloid beta or tau pathology, highlighting INM-901’s broader potential in treating neurodegenerative diseases. The orally administered compound also targets CB1/CB2 receptors and PPARs and has shown improvements in cognition and behavior in long-term animal studies. InMed plans to advance INM-901 through additional preclinical and IND-enabling studies with a lead indication in Alzheimer’s disease.
Stay updated with the latest market activity on Tuesday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.
Looking for insights into the US markets in the middle of the day on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.
Demonstrates statistically significant reduction of pro-inflammatory cytokines, including IL-6, IL-1β, IL-2, and KC/GroSignificantly reduces levels of inflammasome marker, NLRP3, a...
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
InMed Pharmaceuticals shares are trading higher by 45% during Tuesday's session. The company announced that INM-901 reduced Alzheimer 's-related inflammation in a preclinical study.
InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development, and commercialization of rare cannabinoids and proprietary small molecule drug candidates, today reported its financial results for fiscal year 2024, ended June 30, 2024. The company also provided a business update on its pharmaceutical development programs and its strengthened patent portfolio, as well as the sustained revenue growth experienced by its wholly owned subsidiary BayMedica.
InMed Pharmaceuticals’ (NASDAQ: INM) subsidiary BayMedica is positioned amid a growing interest in edibles infused with non-intoxicating minor cannabinoids. These lesser-known cannabinoids offer unique properties and potential health benefits, driving significant market growth. The company published a report on the expansion of the minor cannabinoid market in 2023. “The report, based on data from Headset, the largest industry dataset, explores the growth, competition and consumer trends in ten regulated states, encompassing 85 million of the 158 million residents in areas where recreational cannabis is legal,” reads a recent article. “The report highlights a 5.4% revenue increase in the edible market, with total sales reaching $2.097 billion. This growth is attributed to innovative developments in minor cannabinoid products. Among edible products, gummies demonstrated robust sales, while minor cannabinoid-infused edibles experienced an impressive 47% year-over-year growth, totaling $391 million in sales.”
InMed Pharmaceuticals (NASDAQ: INM), a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors, announced that its drug candidate INM-901 as an oral formulation will be used in its development programs for Alzheimer’s disease following encouraging results obtained in preclinical trials ( https://ibn.fm/D99wp ).
InMed Pharmaceuticals (NASDAQ: INM), a biopharmaceutical company focused on developing proprietary small molecule drug candidates for diseases with high unmet needs, has announced promising outcomes from a long-term preclinical study of its Alzheimer’s Disease (“AD”) drug candidate, INM-901. These new findings confirm and expand upon results from a previous short-term pilot study ( https://ibn.fm/eASUI ).
InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary small molecule drug candidates, today announced its receipt of three patents granted in the U.S., strengthening its patent portfolio. The issued patents include one for its formulation and method of use in the treatment of epidermolysis bullosa and related connective tissue disorders, one for biosynthesis manufacturing processes and one for an ocular drug delivery formulation. As of August 20, 2024, InMed has a total of 13 patent families covering new chemical entities, formulations, manufacturing processes and methods of use.
